Mergers and acquisitions – Page 6
-
BusinessFresenius to buy Akorn and Merck KGaA’s biosimilars
Deals give Fresenius entry into rapidly growing biological drugs market
-
BusinessHow do chemical firms last hundreds of years?
What distinguishes companies that thrive from others that failed?
-
BusinessEU conditionally approves Dow–DuPont merger
To satisfy competition concerns, DuPont will swap crop protection R&D assets for FMC’s nutrition business
-
BusinessShell shrinks stake in Canadian oil sands
$7.25bn sell-off is part of plan to divest over $30bn in assets to reduce debts
-
BusinessAkzoNobel looks to separate chemicals business
Netherlands-based firm rejects PPG takeover bid, and looks to tighten strategic focus on paints and coatings
-
BusinessAramco and Shell end refining relationship
$2.2 billion divorce deal gives Aramco control of biggest oil refinery in the US
-
BusinessCristal deal will make Tronox world’s largest titanium dioxide producer
Tronox to sell alkali business to fund $1.67bn transaction
-
Business$2bn Immunomedics–Seattle Genetics deal delayed amid shareholder infighting
Major investor venBio seeks to derail deal and replace board members
-
BusinessReckitt Benckiser to buy into baby milk
$17bn acquisition of Mead Johnson expands presence in developing markets, especially China
-
BusinessAllergan to buy fat-freezing firm Zeltiq
$2.5bn deal adds to firm’s cosmetic and aesthetic treatments
-
BusinessSabic takes control of Shell petrochemicals joint venture
$820m sale of Saudi Arabian plants continues Shell’s global reorganisation programme
-
BusinessLilly buys CoLucid for migraine drugs
US firm also laying off 485 sales staff after Alzheimer’s drug failure
-
BusinessJ&J to buy Actelion for $30bn
Actelion’s R&D will spin out as a new company, while Janssen will take on in-market and late-stage medicines
-
Business
Novartis on winter deal spree
Swiss company aims to re-stock drug pipeline with three new deals in skin, eye and cardiovascular health
-
BusinessOpening doors to innovation
Chemical companies are increasingly using specialist investment arms to nurture new ideas
-
BusinessIpsen to buy Merrimack’s cancer drugs
$1bn deal covers two liposome-encapsulated formulations of approved therapies
-
BusinessTakeda to buy cancer specialist Ariad
Japan’s largest drug company agrees $5.2bn deal to expand oncology portfolio and boost pipeline
-
BusinessMosaic to buy Vale Fertilizantes in $2.5bn deal
Fertiliser deal continues consolidation trend and expands Mosaic’s presence in Brazil
-
BusinessLinde–Praxair merger further consolidates industrial gases
Deal will leave just three firms controlling 85% of the global market
-
BusinessMylan may lay off up to 3500 staff
The move forms part of the US generic firm’s restructuring efforts